Cargando…

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Donata, Corleis, Björn, Rauch, Susanne, Roth, Nicole, Mühe, Janine, Halwe, Nico Joel, Ulrich, Lorenz, Fricke, Charlie, Schön, Jacob, Kraft, Anna, Breithaupt, Angele, Wernike, Kerstin, Michelitsch, Anna, Sick, Franziska, Wylezich, Claudia, Hoffmann, Bernd, Thran, Moritz, Thess, Andreas, Mueller, Stefan O., Mettenleiter, Thomas C., Petsch, Benjamin, Dorhoi, Anca, Beer, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245475/
https://www.ncbi.nlm.nih.gov/pubmed/34193869
http://dx.doi.org/10.1038/s41467-021-24339-7
_version_ 1783716120562237440
author Hoffmann, Donata
Corleis, Björn
Rauch, Susanne
Roth, Nicole
Mühe, Janine
Halwe, Nico Joel
Ulrich, Lorenz
Fricke, Charlie
Schön, Jacob
Kraft, Anna
Breithaupt, Angele
Wernike, Kerstin
Michelitsch, Anna
Sick, Franziska
Wylezich, Claudia
Hoffmann, Bernd
Thran, Moritz
Thess, Andreas
Mueller, Stefan O.
Mettenleiter, Thomas C.
Petsch, Benjamin
Dorhoi, Anca
Beer, Martin
author_facet Hoffmann, Donata
Corleis, Björn
Rauch, Susanne
Roth, Nicole
Mühe, Janine
Halwe, Nico Joel
Ulrich, Lorenz
Fricke, Charlie
Schön, Jacob
Kraft, Anna
Breithaupt, Angele
Wernike, Kerstin
Michelitsch, Anna
Sick, Franziska
Wylezich, Claudia
Hoffmann, Bernd
Thran, Moritz
Thess, Andreas
Mueller, Stefan O.
Mettenleiter, Thomas C.
Petsch, Benjamin
Dorhoi, Anca
Beer, Martin
author_sort Hoffmann, Donata
collection PubMed
description The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies.
format Online
Article
Text
id pubmed-8245475
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82454752021-07-20 CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 Hoffmann, Donata Corleis, Björn Rauch, Susanne Roth, Nicole Mühe, Janine Halwe, Nico Joel Ulrich, Lorenz Fricke, Charlie Schön, Jacob Kraft, Anna Breithaupt, Angele Wernike, Kerstin Michelitsch, Anna Sick, Franziska Wylezich, Claudia Hoffmann, Bernd Thran, Moritz Thess, Andreas Mueller, Stefan O. Mettenleiter, Thomas C. Petsch, Benjamin Dorhoi, Anca Beer, Martin Nat Commun Article The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies. Nature Publishing Group UK 2021-06-30 /pmc/articles/PMC8245475/ /pubmed/34193869 http://dx.doi.org/10.1038/s41467-021-24339-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hoffmann, Donata
Corleis, Björn
Rauch, Susanne
Roth, Nicole
Mühe, Janine
Halwe, Nico Joel
Ulrich, Lorenz
Fricke, Charlie
Schön, Jacob
Kraft, Anna
Breithaupt, Angele
Wernike, Kerstin
Michelitsch, Anna
Sick, Franziska
Wylezich, Claudia
Hoffmann, Bernd
Thran, Moritz
Thess, Andreas
Mueller, Stefan O.
Mettenleiter, Thomas C.
Petsch, Benjamin
Dorhoi, Anca
Beer, Martin
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
title CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
title_full CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
title_fullStr CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
title_full_unstemmed CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
title_short CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
title_sort cvncov and cv2cov protect human ace2 transgenic mice from ancestral b bavpat1 and emerging b.1.351 sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245475/
https://www.ncbi.nlm.nih.gov/pubmed/34193869
http://dx.doi.org/10.1038/s41467-021-24339-7
work_keys_str_mv AT hoffmanndonata cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT corleisbjorn cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT rauchsusanne cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT rothnicole cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT muhejanine cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT halwenicojoel cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT ulrichlorenz cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT frickecharlie cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT schonjacob cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT kraftanna cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT breithauptangele cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT wernikekerstin cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT michelitschanna cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT sickfranziska cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT wylezichclaudia cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT hoffmannbernd cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT thranmoritz cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT thessandreas cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT muellerstefano cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT mettenleiterthomasc cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT petschbenjamin cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT dorhoianca cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2
AT beermartin cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2